表紙
市場調查報告書

全球慢性阻塞性肺病治療市場:產業分析,規模,佔有率,成長,趨勢,及預測(2019年∼2027年)

Chronic Obstructive Pulmonary Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

出版商 Transparency Market Research 商品編碼 799186
出版日期 內容資訊 英文 193 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球慢性阻塞性肺病治療市場:產業分析,規模,佔有率,成長,趨勢,及預測(2019年∼2027年) Chronic Obstructive Pulmonary Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027
出版日期: 2019年10月16日內容資訊: 英文 193 Pages
簡介

本報告提供全球慢性阻塞性肺病(COPD)治療市場的相關調查,提供市場機會,成長及阻礙因素,各藥物類別·流通管道·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 序文

  • 市場定義·範圍
  • 市場區隔
  • 主要的調查目的
  • 調查亮點

第2章 前提條件及調查方法

第3章 摘要整理

第4章 市場概要

  • 簡介
    • 藥物類別定義
    • 產業的發展/開發
  • 概要
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 市場收益預測
    • 市場收益預測

第5章 市場展望

  • COPD治療的創新解決方案
  • 開發平台分析

第6章 市場分析:各類藥物

  • 概要·定義
  • 主要調查結果/開發
  • 市場收益預測
    • 聯合治療
    • 皮質類固醇
    • 支氣管擴張劑
    • 磷酸二酯酶4抑制劑
    • 代謝動力學
    • 其他
  • 市場魅力分析

第7章 市場分析:各流通管道

  • 引進和定義
  • 主要調查結果/開發
  • 市場收益預測
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 市場魅力分析

第8章 市場分析:各地區

  • 主要調查結果
  • 市場收益預測
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力分析

第9章 北美

第10章 歐洲

第11章 亞太地區

第12章 南美

第13章 中東·非洲

第14章 競爭情形

  • 市場參與企業:競爭矩陣(各企業類別和規模)
  • 市場佔有率/排行榜分析(2018年)
  • 企業簡介
    • AstraZeneca
    • Boehringer Ingelheim International GmbH
    • GlaxoSmithKline plc
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Sunovion Pharmaceuticals Inc. (大日本住友製藥株式會社)
    • CHIESI Farmaceutici SpA
    • Orion Corporation
    • Mylan NV

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Scope of the Report

TMR's report on the global chronic obstructive pulmonary disease (COPD) treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market during the forecast period of 2019 to 2027. The report provides the overall market revenue of the global chronic obstructive pulmonary disease treatment market for the period of 2017-2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global chronic obstructive pulmonary disease treatment market during the forecast period.

The report is prepared after extensive research. Primary research involves bulk of the research efforts, wherein, analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involves referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global COPD treatment market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of the top-down and bottom-up approaches to study various phenomena in the global chronic obstructive pulmonary disease treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global chronic obstructive pulmonary disease treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global chronic obstructive pulmonary disease treatment market.

The report delves into the competition landscape of the global COPD treatment market. Key players operating in the global chronic obstructive pulmonary disease treatment market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOTs are some of the attributes of the players in the global COPD treatment market that have been profiled in this report.

Key Questions Answered in the COPD Treatment Market Report

What is the scope of growth for companies in the global chronic obstructive pulmonary disease treatment market?

What will be the Y-o-Y growth of the global chronic obstructive pulmonary disease treatment market between 2019 and 2027?

Will North America continue to remain the most profitable regional market for COPD treatment providers?

Which factors will impede the growth of the global chronic obstructive pulmonary disease treatment market during the forecast period?

Which are the leading companies in the global COPD treatment market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct a comprehensive research on the growth of the global chronic obstructive pulmonary disease treatment market, and arrive at conclusions on the future growth prospects of the COPD treatment market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary sources referred to by analysts during the production of the global chronic obstructive pulmonary disease treatment market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR's study on the COPD treatment market as primary sources.

These primary and secondary sources have provided exclusive information during interviews, which serves as a validation from chronic obstructive pulmonary disease treatment market leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global chronic obstructive pulmonary disease treatment market with accuracy. The study also uses the top-down approach to assess the numbers for each segment, and the bottom-up approach to counter-validate them. This has helped in reaching TMR's estimates on the future prospects of the global chronic obstructive pulmonary disease treatment market more reliably and accurately.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Class Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, 2017-2027
    • 4.4.1. Market Revenue (US$ Mn) Projection

5. Market Outlook

  • 5.1. Innovative Solutions for COPD Treatment
  • 5.2. Pipeline Analysis

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 6.3.1. Combination Therapy
      • 6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 6.3.1.3. Triple Therapy
      • 6.3.1.4. Others
    • 6.3.2. Corticosteroids
    • 6.3.3. Bronchodilators
      • 6.3.3.1. Long Acting Beta Agonist (LABA)
      • 6.3.3.2. Short Acting Beta Agonist (SABA)
      • 6.3.3.3. Long Acting Muscarinic Antagonist (LAMA)
    • 6.3.4. Phosphodiesterase Type 4 Inhibitors
    • 6.3.5. Mucokinetics
    • 6.3.6. Others
  • 6.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Drug Class

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Retail Pharmacies
    • 7.3.3. Online Pharmacies
  • 7.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by Distribution Channel

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness, by region

9. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 9.2.1. Combination Therapy
      • 9.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 9.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 9.2.1.3. Triple Therapy
      • 9.2.1.4. Others
    • 9.2.2. Corticosteroids
    • 9.2.3. Bronchodilators
      • 9.2.3.1. Long Acting Beta Agonist (LABA)
      • 9.2.3.2. Short Acting Beta Agonist (SABA)
      • 9.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
    • 9.2.4. Phosphodiesterase Type 4 Inhibitors
    • 9.2.5. Mucokinetics
    • 9.2.6. Others
  • 9.3. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
    • 9.5.1. By Drug Class
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country/Sub-region

10. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 10.2.1. Combination Therapy
      • 10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 10.2.1.3. Triple Therapy
      • 10.2.1.4. Others
    • 10.2.2. Corticosteroids
    • 10.2.3. Bronchodilators
      • 10.2.3.1. Long Acting Beta Agonist (LABA)
      • 10.2.3.2. Short Acting Beta Agonist (SABA)
      • 10.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
    • 10.2.4. Phosphodiesterase Type 4 Inhibitors
    • 10.2.5. Mucokinetics
    • 10.2.6. Others
  • 10.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Russia
    • 10.4.7. Rest of Europe
  • 10.5. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
    • 10.5.1. By Drug Class
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 11.2.1. Combination Therapy
      • 11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 11.2.1.3. Triple Therapy
      • 11.2.1.4. Others
    • 11.2.2. Corticosteroids
    • 11.2.3. Bronchodilators
      • 11.2.3.1. Long Acting Beta Agonist (LABA)
      • 11.2.3.2. Short Acting Beta Agonist (SABA)
      • 11.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
    • 11.2.4. Phosphodiesterase Type 4 Inhibitors
    • 11.2.5. Mucokinetics
    • 11.2.6. Others
  • 11.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Retail Pharmacies
    • 11.3.3. Online Pharmacies
  • 11.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
    • 11.5.1. By Drug Class
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 12.2.1. Combination Therapy
      • 12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 12.2.1.3. Triple Therapy
      • 12.2.1.4. Others
    • 12.2.2. Corticosteroids
    • 12.2.3. Bronchodilators
      • 12.2.3.1. Long Acting Beta Agonist (LABA)
      • 12.2.3.2. Short Acting Beta Agonist (SABA)
      • 12.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
    • 12.2.4. Phosphodiesterase Type 4 Inhibitors
    • 12.2.5. Mucokinetics
    • 12.2.6. Others
  • 12.3. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 12.3.1. Hospital Pharmacies
    • 12.3.2. Retail Pharmacies
    • 12.3.3. Online Pharmacies
  • 12.4. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
    • 12.5.1. By Drug Class
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
    • 13.2.1. Combination Therapy
      • 13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 13.2.1.3. Triple Therapy
      • 13.2.1.4. Others
    • 13.2.2. Corticosteroids
    • 13.2.3. Bronchodilators
      • 13.2.3.1. Long Acting Beta Agonist (LABA)
      • 13.2.3.2. Short Acting Beta Agonist (SABA)
      • 13.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
    • 13.2.4. Phosphodiesterase Type 4 Inhibitors
    • 13.2.5. Mucokinetics
    • 13.2.6. Others
  • 13.3. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
    • 13.3.1. Hospital Pharmacies
    • 13.3.2. Retail Pharmacies
    • 13.3.3. Online Pharmacies
  • 13.4. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
    • 13.4.1. GCC
    • 13.4.2. South Africa
    • 13.4.3. Israel
    • 13.4.4. Rest of Middle East & Africa
  • 13.5. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis
    • 13.5.1. By Drug Class
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share/ranking Analysis By Company (2018)
  • 14.3. Company Profiles
    • 14.3.1. AstraZeneca
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Company Financials
      • 14.3.1.3. Growth Strategies
      • 14.3.1.4. SWOT Analysis
    • 14.3.2. Boehringer Ingelheim International GmbH
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Company Financials
      • 14.3.2.3. Growth Strategies
      • 14.3.2.4. SWOT Analysis
    • 14.3.3. GlaxoSmithKline plc
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Company Financials
      • 14.3.3.3. Growth Strategies
      • 14.3.3.4. SWOT Analysis
    • 14.3.4. Novartis AG
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Company Financials
      • 14.3.4.3. Growth Strategies
      • 14.3.4.4. SWOT Analysis
    • 14.3.5. Teva Pharmaceutical Industries Ltd.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Company Financials
      • 14.3.5.3. Growth Strategies
      • 14.3.5.4. SWOT Analysis
    • 14.3.6. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Company Financials
      • 14.3.6.3. Growth Strategies
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. CHIESI Farmaceutici S.p.A.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Company Financials
      • 14.3.7.3. Growth Strategies
      • 14.3.7.4. SWOT Analysis
    • 14.3.8. Orion Corporation
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Company Financials
      • 14.3.8.3. Growth Strategies
      • 14.3.8.4. SWOT Analysis
    • 14.3.9. Mylan N.V.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Company Financials
      • 14.3.9.3. Growth Strategies
      • 14.3.9.4. SWOT Analysis

List of Tables

  • Table 01: Pipeline Analysis
  • Table 02: Pipeline Analysis
  • Table 03: Pipeline Analysis
  • Table 04: Pipeline Analysis
  • Table 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017-2027
  • Table 07: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017-2027
  • Table 08: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 09: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Region, 2017-2027
  • Table 10: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 11: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017-2027
  • Table 12: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017-2027
  • Table 13: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 14: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country, 2017-2027
  • Table 15: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 16: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017-2027
  • Table 17: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017-2027
  • Table 18: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 19: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 20: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 21: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017-2027
  • Table 22: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017-2027
  • Table 23: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 24: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 25: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 26: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017-2027
  • Table 27: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017-2027
  • Table 28: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 29: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027
  • Table 30: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Drug Class, 2017-2027
  • Table 31: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Combination Therapy, 2017-2027
  • Table 32: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Bronchodilators, 2017-2027
  • Table 33: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017-2027
  • Table 34: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017-2027

List of Figures

  • Figure 01: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) and Distribution, by Region, 2018 and 2027
  • Figure 02: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Drug Class, 2018
  • Figure 03: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 04: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Combination Therapy, 2017-2027
  • Figure 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Bronchodilators, 2017-2027
  • Figure 07: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Corticosteroids, 2017-2027
  • Figure 08: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Phosphodiesterase Type 4 Inhibitor, 2017-2027
  • Figure 09: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Mucokinetics, 2017-2027
  • Figure 10: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2017-2027
  • Figure 11: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 12: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2019 and 2027
  • Figure 13: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2017-2027
  • Figure 14: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2017-2027
  • Figure 15: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2017-2027
  • Figure 16: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 17: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Region, 2018 and 2027
  • Figure 18: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Region, 2019-2027
  • Figure 19: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 20: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 21: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027
  • Figure 23: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 24: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country, 2018 and 2027
  • Figure 25: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country, 2019-2027
  • Figure 26: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 27: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 28: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027

"Figure 29: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

  • Figure 30: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019-2027
  • Figure 31: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 32: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 33: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 34: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 35: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027

"Figure 36: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

  • Figure 37: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 - 2027
  • Figure 38: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 39: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 40: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 41: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 42: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027

"Figure 43: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

  • Figure 44: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019 - 2027
  • Figure 45: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 46: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 47: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2027
  • Figure 48: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2018 and 2027
  • Figure 49: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2019-2027

"Figure 50: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2018 and 2027

  • Figure 51: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2019?2027
  • Figure 52: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
  • Figure 53: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019-2027
  • Figure 54: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share, by Company, 2018
  • Figure 55: AstraZeneca Respiratory Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 56: AstraZeneca R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 57: AstraZeneca Breakdown of Net Sales (%), by Region, 2018
  • Figure 58: AstraZeneca Breakdown of Net Sales (%), by Product Segment, 2018
  • Figure 59: Boehringer Ingelheim International GmbH, Human Pharmaceuticals Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 60: Boehringer Ingelheim International GmbH R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 61: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Region, 2018
  • Figure 62: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 63: GlaxoSmithKline plc Respiratory (Pharmaceuticals) Business Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 64: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 65: GlaxoSmithKline plc Breakdown of Net Sales (%), by Region, 2018
  • Figure 66: GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 67: Novartis AG COPD Portfolio Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 68: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 69: Novartis AG Breakdown of Net Sales (%), by Country, 2018
  • Figure 70: Novartis AG Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 71: Teva Pharmaceutical Industries Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 72: Teva Pharmaceutical Industries Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 73: Teva Pharmaceutical Industries Ltd Breakdown of Net Sales (%), by Geography, 2018
  • Figure 74: Sumitomo Dainippon Pharma Co., Ltd Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 75: Sumitomo Dainippon Pharma Co., Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 76: Sumitomo Dainippon Pharma Co., Ltd Breakdown of Net Sales (%), by Geography, 2018
  • Figure 77: Sumitomo Dainippon Pharma Co., Ltd Breakdown of Net Sales (%), by Product Segment, 2018
  • Figure 78: CHIESI Farmaceutici S.p.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 79: CHIESI Farmaceutici S.p.A. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 80: CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Geography, 2018
  • Figure 81: CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Therapeutic Area(Business Segment), 2018
  • Figure 82: Orion Corporation Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 83: Orion Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
  • Figure 84: Orion Corporation Breakdown of Net Sales (%), by Geography, 2018
  • Figure 85: Orion Corporation Breakdown of Net Sales (%), by Business Segment, 2018
  • Figure 86: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2018
  • Figure 87: Mylan N.V. Breakdown of Net Sales, by Geography, 2018
  • Figure 88: Mylan N.V. R&D Expenses (US$ Mn), 2017 and 2018
Back to Top